Myeloma Patients Europe (MPE) is working to develop useful information materials and resources for members and patients on COVID-19 (coronavirus). If you feel there is a need for these materials to be translated into your language, please email vallejo@mpeurope.org
To understand how we could best help, MPE conducted research to learn more about the impact of the pandemic and lockdown measures, and the needs of patients, carers and member organisations. A survey of 28 members in April 2021 revealed a significant emotional and psychosocial impact, as well as treatment delays and problems accessing wider healthcare and support services in some countries. Although members were adapting, some had concerns over their financial resilience and future organisational sustainability.
Read the full report here.
Through our COVID-19 Outreach Workstream, and as part of our mission to provide education, information, and support to members and to advocate at European, national, and local levels, MPE began research to learn more about the effects of COVID-19 on the patient community. MPE has published a report summarising the results of a series of semi-structured focus groups conducted to collect personal experiences and broader insights from patients and caregivers.
Read the full report here.
The SARS-CoV-2 (COVID-19) pandemic has raised a lot of questions, especially around vaccination. With this Q&A we hope to answer some of the most frequently asked questions about the current approved vaccines in Europe and how they affect to myeloma and AL amyloidosis patients.
Read more.
Myeloma Patients Europe (MPE) has received a range of queries from members, myeloma patients and AL amyloidosis patients about the impact that the COVID-19 (coronavirus) situation is having on treatment and care. To answer these questions and to understand the impact in different European countries, MPE has been speaking to experts and reviewing national treatment guidance. Here is a Question and Answer (Q&A) on how treatment, hospital appointments and clinical trials may be affected for patients..
Read the full report here.
To understand how we could best help, MPE conducted research to learn more about the impact of the pandemic and lockdown measures, and the needs of patients, carers and member organisations. A survey of 28 members in April 2021 revealed a significant emotional and psychosocial impact, as well as treatment delays and problems accessing wider healthcare and support services in some countries. Although members were adapting, some had concerns over their financial resilience and future organisational sustainability.
Read the full report here.
The increase in the number of people affected by COVID-19 has generated great concern, and has forced a number of countries to implement strict measures to stop the spread of the virus. These measures are, in many countries, very restrictive and can include social distancing, self-quarantine and self-isolation. With the help of Fátima Castaño, psycho-oncologist, MPE has collated some tips to help you to cope, in the best way possible, with confinement.
Read the full report here.
Find here an infographic highlighting tips that will help you to cope, in the best way possible, with confinement.
Read the full report here.
MPE has put together an advice sheet for our members and myeloma patients on COVID-19. This advice has been reviewed by our scientific advisors and will be continually updated to reflect the latest information.
Read the full report here.
Infographic on COVID-19
Infographic supporting the advice sheet developed for MPE members and myeloma patients on COVID-19.